Testing Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: Current Status and Near‑Future Outlook

Česká verze

Authors: Pavel Dundr ¹; Radoslav Matěj ^1,2,3
Authors place of work: Ústav patologie 1. LF UK a VFN v Praze ¹; Ústav patologie 3. LF UK a Fakulní nemocnice Královské Vinohrady ²; Oddělení patologie, 3. LF UK a Fakultní Thomayerova nemocnice ³
Published in the journal: Čes.-slov. Patol., 62, 2026, No. 1, p. 13-16
Category: Přehledový článek

Summary

Claudin 18.2 (CLDN18.2) represents one of the newest biomarkers expected to enter routine testing in the near future and expanding the spectrum of available predictive markers. It is currently a clinically relevant predictor for adenocarcinomas of the stomach and the gastroesophageal junction, although its use will likely extend also to other diagnoses. The aim of this report is to provide an overview of selected aspects of CLDN18.2 expression testing, including the choice of appropriate tissue, the issue of tumor heterogeneity, antibodies suitable for testing and their evaluation, where such testing can be performed, and the prospects for the future.

Keywords:

gastric adenocarcinoma – claudin 18.2 – adenocarcinoma of the gastroesophageal junction

Zdroje

1. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mfolfox6 in patients with cldn18. 2-positive, her2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (spotlight): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2023; 401(10389): 1655-1668.

2. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus capox in cldn18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 glow trial. Nat Med 2023; 29(8): 2133-2141.

3. Nakayama I, Qi C, Chen Y, et al. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 2024; 21(5): 354-369.

4. Hashimoto T, Iida N, Nakamura Y, et al. Landscape analysis of cldn18 expression and isoform distribution in solid tumors: Insights from monstar-screen-2 study. Cancer Sci 2025; 116(8): 2218-2231.

5. Angerilli V, Sacchi D, Rizzato M, et al. Claudin 18.2: A promising actionable target in biliary tract cancers. ESMO Open 2025; 10(5): 105049.

6. Arseneau RJ, Kempster E, Bekkers C, et al. Claudin 18 (43-14a clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy. Transl Oncol 2025; 55(102362.

7. Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: A tissue microarray study of 523 molecularly profiled cases. Br J Cancer 2019; 121(3): 257-263.

8. Kim M, Woo HY, Kim J, Seo AN. Claudin 18.2 expression in gastric tumors and other tumor types with gastric epithelium-like differentiation. In Vivo 2025; 39(3): 1540-1553.

9. Jasani B, Taniere P, Schildhaus HU, et al. Global ring study to investigate the comparability of total assay performance of commercial claudin 18 antibodies for evaluation in gastric cancer. Lab Invest 2024; 104(1): 100284.

10. Rocken C, Hohn AK, Neumann J, et al. Concordance of laboratory assays for claudin 18.2 in gastric cancer tissue samples: Independent proficiency testing and a descriptive non -⁠ -interventional study. Virchows Arch 2025; 487(5):1117-1125.

11. Baek JH, Park DJ, Kim GY, et al. Clinical implications of claudin18.2 expression in patients with gastric cancer. Anticancer Res 2019; 39(12): 6973-6979.

12. Liu BL, Cleary JM, Shi J, Hornick JL, Zhao L. Claudin 18.2 and other therapeutic biomarkers in gastric and gastroesophageal junction adenocarcinomas. Am J Surg Pathol 2025; 49(12): 1233-1244.

13. Son SM, Woo CG, Lee OJ, et al. Discordance in claudin 18.2 expression between primary and metastatic lesions in patients with gastric cancer. J Gastric Cancer 2025; 25(2): 303 -⁠ 317.

14. Choi E, Shin J, Ryu MH, Kim HD, Park YS. Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep 2024; 14(1): 17648.

15. Ogawa H, Abe H, Yagi K, Seto Y, Ushiku T. Claudin-18 status and its correlation with her2 and pd-l1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer 2024; 27(4): 802-810.

16. Luchini C, Matkowskyj KA, Kuwata T, et al. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: Review and recommendations for routine testing and scoring. Virchows Arch 2025; 487(3): 487 -⁠ 499.

17. Desai N, Ko HM, Lee M, et al. Claudin 18 immunohistochemistry in cholangiocarcinoma. J Gastrointest Oncol 2025; 16(2): 671 -⁠ 678.

18. Kinzler MN, Gretser S, Schulze F, et al. Expression of claudin-18.2 in cholangiocarcinoma: A comprehensive immunohistochemical analysis from a german tertiary centre. Histopathology 2025; 86(4): 640-646.